Clearwater Analytics is poised for growth with strong revenue projections and potential synergies. Read here for an analysis ...

On August 29, 2024, Enfusion, Inc. (NYSE:ENFN) stock closed at $8.20 per share with a market capitalization of $764.328 million. NCG Small Cap Strategy stated the following regarding Enfusion, Inc ...

We recently published a list of 10 Small–Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a look at where Enfusion, Inc. (NYSE:ENFN) stands against other small ...

Michael Spellacy, Chair of the Enfusion Board and a member of the Enfusion Special Committee, said, “ Our agreement with Clearwater represents the culmination of a comprehensive process to ...

Enfusion shows promise with 21% medium-term growth targets, positive free cash flow, GAAP profitability, and no debt, benefiting from falling interest rates. Despite no significant economic moat ...

During Q4, Enfusion generated revenue of $40.5 million, which was up more than 27% from the same quarter of 2021. This was right at the high end of management's guidance.

Enfusion ENFN is set to report first-quarter 2023 results on May 9. For the quarter, the Zacks Consensus Estimate for revenues is currently pegged at $42.27 million, suggesting growth of 23.83% ...

Enfusion shareholders are down 55% for the year, even worse than the market loss of 23%. That's disappointing, but it's worth keeping in mind that the market-wide selling wouldn't have helped.

Enfusion was recognized by Aite Group as "Best in Class" for its Front-to-Back Portfolio Management System in 2019 and was named "Best Managed Services Provider" at the 2020 HFM EU Services Awards.

Enfusion , a U.S. software provider for asset managers, is in talks with investment bankers to evaluate options that could include a potential sale, according to people familiar with the matter.